Metabolic Disorders News and Research

RSS

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Sanofi-aventis announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.

25 Mar 2011

Gut bacteria and state of immune system influence personality

Researchers at McMaster University discovered that the "cross-talk" between bacteria in our gut and our brain plays an important role in the development of psychiatric illness, intestinal diseases and probably other health problems as well including obesity.

24 Mar 2011

Insight into photodermatoses

One in ten people react to sunlight by developing eczema. This abnormal reaction is one of a group of disorders known as photodermatoses.

17 Mar 2011

Study: Role of air pollutants in cardiometabolic syndrome

To explore one of the most critical health/environment intersections - how the very air we breathe can cause heart disease and diabetes and contribute to the problems of obesity - Michigan State University has been named a Clean Air Research Center by the Environmental Protection Agency.

8 Mar 2011

Worldwide collaborative project to improve newborn screening accuracy for metabolic disorders

A unique worldwide collaborative project takes advantage of the Internet to improve the accuracy of screening for rare metabolic disorders in newborns, reports a paper in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

4 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Sanfilippo disease is a rare disorder caused by the failure of enzymes to break down specific kinds of complex carbohydrates, resulting in their accumulation in cells and often severe physical and neurological problems - and sometimes early death.

1 Mar 2011

Kentucky, Virginia LapBand centers install Crospon's EndoFLIP system

Crospon, an Irish medical device developer based in Galway, has announced that its EndoFLIP system is now being used in two leading LapBand centers in Kentucky and Virginia.

19 Feb 2011

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announced today the grant of US Patent No. 7,884,318 entitled "Systems, Methods, and Computer-Readable Medium for Determining Composition of Chemical Constituents in a Complex Mixture".

8 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

Lancet series examines health challenges in India

"Indians are growing richer, but they are also adopting unhealthy lifestyles that could take years off their lives and threaten economic growth," according to an article published in Lancet Tuesday, Agence France-Presse reports (1/11). The article is one of seven published in the Lancet as part of a series that also includes a set of commentary pieces on health issues facing the country (1/11).

12 Jan 2011

Neurology professor receives MFRF's 'See the Light' award for Tay-Sachs research

Miguel Sena-Esteves, PhD, associate professor of neurology at the University of Massachusetts Medical School, was presented with the annual "See the Light" award from the Mathew Forbes Romer Foundation in recognition of his work for leading the fight against children's genetic diseases of the brain.

12 Jan 2011

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.

10 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.